Abstract
Synergy with no overlapping toxicities has been demonstrated for the combination of irinotecan (Camptosar, CPT-11) and gemcitabine (Gemzar) in vitro. Results of a single-institution phase I study in which patients with previously untreated pancreatic cancer were given irinotecan and gemcitabine were promising, with two of three patients achieving a partial response. Because of the favorable outcome of the phase I study, a multicenter phase II trial was undertaken in previously untreated patients with pancreatic carcinoma. Data from other sites entering patients in this phase II study have been analyzed, and a multicenter phase III trial of single-agent gemcitabine vs the irinotecan combination in first-line treatment of patients with locally advanced or metastatic pancreatic cancer is underway.
| Original language | English |
|---|---|
| Pages (from-to) | 31-33 |
| Number of pages | 3 |
| Journal | Oncology |
| Volume | 14 |
| Issue number | 12 SUPPL. 14 |
| State | Published - Dec 1 2000 |
Fingerprint
ASJC Scopus subject areas
- Oncology
Cite this
Irinotecan in the management of patients with pancreatic cancer. / Green, Mark R.; Harper, Melinda; Safa, Ahmad; Sherman, Carol A.; Mushtaq, Chaudry M.; Bahadori, Hamid; Brescia, Frank J.; Rocha Lima, Caio M S P.
In: Oncology, Vol. 14, No. 12 SUPPL. 14, 01.12.2000, p. 31-33.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Irinotecan in the management of patients with pancreatic cancer
AU - Green, Mark R.
AU - Harper, Melinda
AU - Safa, Ahmad
AU - Sherman, Carol A.
AU - Mushtaq, Chaudry M.
AU - Bahadori, Hamid
AU - Brescia, Frank J.
AU - Rocha Lima, Caio M S P
PY - 2000/12/1
Y1 - 2000/12/1
N2 - Synergy with no overlapping toxicities has been demonstrated for the combination of irinotecan (Camptosar, CPT-11) and gemcitabine (Gemzar) in vitro. Results of a single-institution phase I study in which patients with previously untreated pancreatic cancer were given irinotecan and gemcitabine were promising, with two of three patients achieving a partial response. Because of the favorable outcome of the phase I study, a multicenter phase II trial was undertaken in previously untreated patients with pancreatic carcinoma. Data from other sites entering patients in this phase II study have been analyzed, and a multicenter phase III trial of single-agent gemcitabine vs the irinotecan combination in first-line treatment of patients with locally advanced or metastatic pancreatic cancer is underway.
AB - Synergy with no overlapping toxicities has been demonstrated for the combination of irinotecan (Camptosar, CPT-11) and gemcitabine (Gemzar) in vitro. Results of a single-institution phase I study in which patients with previously untreated pancreatic cancer were given irinotecan and gemcitabine were promising, with two of three patients achieving a partial response. Because of the favorable outcome of the phase I study, a multicenter phase II trial was undertaken in previously untreated patients with pancreatic carcinoma. Data from other sites entering patients in this phase II study have been analyzed, and a multicenter phase III trial of single-agent gemcitabine vs the irinotecan combination in first-line treatment of patients with locally advanced or metastatic pancreatic cancer is underway.
UR - http://www.scopus.com/inward/record.url?scp=0034564489&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034564489&partnerID=8YFLogxK
M3 - Article
C2 - 11200146
AN - SCOPUS:0034564489
VL - 14
SP - 31
EP - 33
JO - ONCOLOGY (United States)
JF - ONCOLOGY (United States)
SN - 0890-9091
IS - 12 SUPPL. 14
ER -